熱門資訊> 正文

Mesobster报告称，由于Ryonspel销售强劲，第二季度收入激增66%

2025-10-07 12:34

Mesoblast (OTCPK:MEOBF) reported US$21.9M in gross revenue for the quarter ended September 30, 2025.
This marks a 66% increase compared to the previous quarter.
Growth driven by strong sales of Ryoncil (remestemcel-L-rknd).
Ryoncil is the first FDA-approved mesenchymal stromal cell therapy. It remains the only approved treatment for children under 12 with steroid-refractory acute graft-versus-host disease (SR-aGvHD).
Source: Press release

More on Mesoblast

Mesoblast Limited (MESO) Q4 2025 Earnings Call Transcript
Mesoblast Limited 2025 Q4 - Results - Earnings Call Presentation
Seeking Alpha’s Quant Rating on Mesoblast
Historical earnings data for Mesoblast
Financial information for Mesoblast

推薦文章

風險及免責提示：以上內容僅代表作者的個人立場和觀點，不代表華盛的任何立場，華盛亦無法證實上述內容的真實性、準確性和原創性。投資者在做出任何投資決定前，應結合自身情況，考慮投資產品的風險。必要時，請諮詢專業投資顧問的意見。華盛不提供任何投資建議，對此亦不做任何承諾和保證。